Showing results (151-160 of 202) with videos related to
Sort By:
Pageof 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2008
Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECTStephen Chia, William Gradishar, Louis Mauriac, et al.Journal of Managed Care & Specialty Pharmacy|July 27, 2026
Economic value of ribociclib in early breast cancer in the United StatesAdam Brufsky, Sara M Tolaney, Vijayakrishna K Gadi, et al.Journal of the National Cancer Institute|September 21, 2010
CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancerXinhui Wang, Takuya Osada, Yangyang Wang, et al.Medrxiv : the Preprint Server for Health Sciences|September 15, 2025
Interim Analysis of Dose-Escalated Preoperative Breast Irradiation: A Phase Ib studyRavi Patel, Emilia Diego, Hayeon Kim, et al.The Lancet. Oncology|February 11, 2024
Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trialCarlo Palmieri, Hannah Linden, Stephen N Birrell, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2018
Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast CancerSarah Croessmann, Luigi Formisano, Lisa N Kinch, et al.The New England Journal of Medicine|October 22, 2025
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast CancerJavier Cortés, Kevin Punie, Carlos Barrios, et al.Breast Cancer Research and Treatment|May 11, 2022
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancerJoyce O'Shaughnessy, Adam Brufsky, Hope S Rugo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2012
Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acidMiguel Martin, Richard Bell, Hugues Bourgeois, et al.Clinical Breast Cancer|July 5, 2011
A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancerAdam Brufsky, Karen Hoelzer, Thaddeus Beck, et al.Pageof 21